Supporting Information

General Chemistry Information
All reactions were performed under a dry atmosphere of nitrogen unless otherwise specified. Indicated reaction temperatures refer to the reaction bath, while room temperature (rt) is noted as 25 °C. Commercial grade reagents and anhydrous solvents were used as received from vendors and no attempts were made to purify or dry these components further. 3-(2-(trifluoromethyl)phenyl)azetidine hydrochloride was purchased from Small Molecules [CAS number 1203684-79-0] . 2,3,4,5-Tetrahydro-1H-benzo [d] azepine was purchased from Acros . Tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate hemioxalate was purchased from Alfa [CAS number 1041026-71-4] . 2,3-Dihydrospiro[indene-1,4'-piperidine] hydrochloride was purchased from Matrix Scientific . Removal of solvents under reduced pressure was accomplished with a Buchi rotary evaporator at approximately 28 mm Hg pressure using a Teflon-linked KNF vacuum pump. Thin layer chromatography was performed using 1" x 3" AnalTech No. 02521 silica gel plates with fluorescent indicator. Visualization of TLC plates was made by observation with either short wave UV light (254 nm lamp), 10% phosphomolybdic acid in ethanol or in iodine vapors. Preparative thin layer chromatography was performed using Analtech, 20 × 20 cm, 1000 micron preparative TLC plates. Flash column chromatography was carried out using a Teledyne Isco CombiFlash Companion Unit with RediSep ® Rf silica gel columns. If needed, products were purified by reverse phase chromatography, using a Teledyne Isco CombiFlash Companion Unit with RediSep ® Gold C18 reverse phase column. Proton NMR spectra were obtained either on 300 MHz Bruker Nuclear Magnetic Resonance Spectrometer or 500 MHz Bruker Nuclear Magnetic Resonance Spectrometer and chemical shifts Bruker Nuclear Magnetic Resonance Spectrometer and chemical shifts ( are reported in parts per million (ppm) and coupling constant (J) values are given in Hz, with the following spectral pattern designations: s, singlet; d, doublet; t, triplet, q, quartet; dd, doublet of doublets; m, multiplet; br, broad. Tetramethylsilane was used as an internal reference. Melting points are uncorrected and were obtained using a MEL-TEMP Electrothermal melting point apparatus. Mass spectroscopic analyses were performed using positive mode electron spray ionization (ESI) on a Varian ProStar LC-MS with a 1200L quadrapole mass spectrometer. High pressure liquid chromatography (HPLC) purity analysis was performed using a Varian Pro Star HPLC system with a binary solvent system A and B using a gradient elusion [A, H 2 O with 0.05% trifluoroacetic acid (TFA); B, CH 3 CN with 0.05% TFA] and flow rate = 1 mL/min, with UV detection at 223 nm. All final compounds were purified to ≥95% purity by the Varian Pro Star HPLC system using the following methods: A) Phenomenex C18 (2) 
RBP4 In Vitro Assay Information
In vitro binding of compounds to RBP4. Analogue binding affinities for RBP4 were measured using our previously described scintillation proximity assay (SPA). Non-linear regression analysis conducted following saturation binding of retinol to RBP4 revealed a Kd of 62.5 nM in our assay conditions which is in line with the previously reported 70-190 nM range of values.
2 For compound characterization we measured the competitive displacement of radiolabeled retinol added to the reaction mix at 10 nM which roughly corresponds to the generally recommended 1/10 of the Kd concentration of radioligand. The IC 50 values were calculated from the 12-point compound titrations using a four-parameter logistic equation. Compounds with appreciable RBP4 binding potency (generally, with IC 50 <150 nM) were further assessed for the ability to antagonize the retinol-dependent RBP4-TTR interaction using the HTRF assay.
S4
Assessment of antagonistic activity in the HTRF RBP4-TTR interaction assay. The analogue ability to disrupt the retinol-induced interaction of RBP4 with TTR was examined using the previously described HTRF assay 33 that probes retinol-dependent RBP4-TTR interaction. As indicated in the Experimental Section, we used bacterially expressed Maltose Binding Protein (MBP)-tagged RBP4 and commercially available TTR labeled directly with Eu 3+ cryptate along with a d2-conjugated anti-MBP monoclonal antibody in order to implement this assay. Retinol added to the reaction mix at 1 µM concentration stimulates RBP4-TTR interaction which brings europium in close proximity to the d2 dye with the following fluorescence energy transfer (FRET) to d2. The FRET signal, measured as a 668 nm emission, was normalized using the 620 nm europium emission to compensate for the pipetting and dispensing errors. Following a 12-point dose titration (20 µM -0.1 nM) the IC 50 values were calculated using a standard four parameter logistic nonlinear regression model equation. In order to monitor a correlation between the binding affinity of compounds for RBP4 and their potency as antagonists of the retinoldependent RBP4-TTR interaction we tracked a ratio of IC 50 values in the HTRF and SPA assays. Despite the difference in binding potency, for the majority of analogues this ratio tended to be within the 5-20 range.
RBP4 In Vivo PD (Serum RBP4 Measurements) Information
Blood samples were collected from a tail vein. Whole blood was drawn into a centrifuge tube and was allowed to clot at room temperature for 30 minutes followed by centrifugation at 2000g for 15 minutes at 48 C to collect serum. Serum RBP4 was measured using the RBP4 (mouse/rat) dual ELISA kit (Enzo Life Sciences, Farmingdale, NY) following the manufacturer's instructions.
In Vivo PK Information and Data
The objective of this study was to determine the pharmacokinetics of analogue 43 in plasma and to determine the extent of urinary excretion of 43 following single intravenous or oral dose administration to male rats. The pharmacokinetics and urinary excretion of 43 also were determined following single daily oral dose administration for seven consecutive days. In addition, plasma and urine samples were collected for subsequent analysis for a specific biomarker of drug activity.
TEST ARTICLE AND VEHICLE INFORMATION:
IV dosing vehicle:
3% N,N-dimethylacetamide/ 45% PEG300/ 12% EtOH/ 40% sterile H 2 O PO dosing vehicle: 2% Tween 80 in 0.9% saline Dose formulation:
The dose formulation for IV administration was prepared in vehicle to contain test compound at a nominal concentration of 0.25 mg/mL. The dose formulation was prepared by the step-wise addition (in the order listed) of the individual components of the vehicle to a weighed quantity of test compound in a volume that yielded the desired final concentration. Dose formulations for PO administration were prepared in vehicle to contain a nominal concentration of test compound of 1 mg/mL. Each formulation was prepared by mixing a weighed quantity of test compound with the appropriate volume of vehicle. Handling:
Room temperature. Stability: Dose formulations were prepared fresh on each day of dosing; considered stable through use for dosing.
S5
Disposition: Unused dose formulations were discarded after dosing. No consumable enrichment was provided. Acclimation Period:
Minimum of 2 days. Prior to study start, the animals were observed for general health and acceptability for use.
EXPERIMENTAL DESIGN:
Group Assignment and Animal Identification: Catheter patency was ascertained on Day 0. The animals then were arbitrarily assigned to dose groups as indicated in Table 1 . Each animal was given an identification number for this study by ear punch. Upon centrifugation, an approximate 5-10 L portion of each plasma sample was removed for subsequent biomarker analysis and immediately frozen; in addition, an approximate 300 L portion of the 48-hr plasma sample collected from animals in Group 3 was removed for subsequent blood chemistry analysis and immediately frozen. The remainder of each plasma sample was frozen for subsequent analysis for drug concentration. All plasma samples were stored at or below -70 ºC.
Urine Collection: Urine samples were collected from animals housed in plastic metabolism cages. Urine was collected over ice and samples were obtained at the intervals indicated in the Group Assignment table. The volume of each urine sample was measured and recorded.
Urine Storage: An approximate 5-10 L portion of each urine sample were removed for subsequent biomarker analysis and immediately frozen; the remainder of each urine sample was frozen for subsequent analysis for drug concentration. All urine samples were stored at or below -70 ºC.
EUTHANASIA:
Euthanasia Intervals and Method: Following the last blood/urine collection. CO 2 asphyxia.
Drug Level Analyses and Pharmacokinetics (PK):
Plasma and urine samples were analyzed for drug levels using a discovery grade HPLC/MS/MS method. Plasma drug concentration versus time data for S7 animals in Groups 1, 2, and 3 were subjected to pharmacokinetic analysis using WinNonlin ® (Version 4.1; Pharsight Corp.; Cary, NC). Data were subjected to non-compartmental analysis using WinNonlin® Model 200 (for extravascular administration); a uniform weighting factor was applied to each data set. Tmax and Cmax values were determined directly from the data. AUClast and AUC INF values were calculated using the log/linear trapezoidal (IV dose) or linear up/log down trapezoidal (PO dose). Halflife values were calculated from the first order rate constant associated with the observed terminal portion of the plasma drug concentration versus time curve, as estimated by regression analysis, using a minimum of three non-zero time points after Tmax. The regression with the largest adjusted R 2 (square of the correlation coefficient) was selected as the best fit. Regression fits with an adjusted R 2 of less than 0.800 were considered to be unreliable and were excluded from inclusion in the tabulation of kinetic parameters. Mean values and standard deviations for the pharmacokinetic parameters were calculated using WinNonlin. Final Glide scores calculated using Glide XP after alignment to the co-crystalized conformation of A1120 and with Impact minimization.
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